vs
Prime Medicine, Inc.（PRME）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
REZOLVE AI PLC的季度营收约是Prime Medicine, Inc.的1.4倍（$1.2M vs $838.0K），REZOLVE AI PLC净利率更高（-1078.8% vs -5498.7%，领先4419.9%）
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
PRME vs RZLV — 直观对比
营收规模更大
RZLV
是对方的1.4倍
$838.0K
净利率更高
RZLV
高出4419.9%
-5498.7%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $838.0K | $1.2M |
| 净利润 | $-46.1M | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | -5800.5% | -808.4% |
| 净利率 | -5498.7% | -1078.8% |
| 营收同比 | -61.6% | — |
| 净利润同比 | -9.0% | — |
| 每股收益（稀释后） | $-0.22 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRMERZLV
| Q4 25 | $838.0K | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.1M | $1.2M | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $2.2M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $591.0K | — | ||
| Q4 23 | $0 | — |
净利润PRMERZLV
| Q4 25 | $-46.1M | — | ||
| Q3 25 | $-50.6M | — | ||
| Q2 25 | $-52.6M | $-13.0M | ||
| Q1 25 | $-51.9M | — | ||
| Q4 24 | $-42.3M | — | ||
| Q2 24 | $-55.3M | — | ||
| Q1 24 | $-45.8M | — | ||
| Q4 23 | $-65.6M | — |
营业利润率PRMERZLV
| Q4 25 | -5800.5% | — | ||
| Q3 25 | -4406.0% | — | ||
| Q2 25 | -4787.2% | -808.4% | ||
| Q1 25 | -3603.3% | — | ||
| Q4 24 | -2025.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -8179.5% | — | ||
| Q4 23 | — | — |
净利率PRMERZLV
| Q4 25 | -5498.7% | — | ||
| Q3 25 | -4129.1% | — | ||
| Q2 25 | -4716.7% | -1078.8% | ||
| Q1 25 | -3568.8% | — | ||
| Q4 24 | -1936.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -7743.0% | — | ||
| Q4 23 | — | — |
每股收益（稀释后）PRMERZLV
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.32 | — | ||
| Q2 25 | $-0.41 | — | ||
| Q1 25 | $-0.40 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q2 24 | $-0.46 | — | ||
| Q1 24 | $-0.44 | — | ||
| Q4 23 | $-0.72 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $120.9M | $-14.3M |
| 总资产 | $342.7M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRMERZLV
| Q4 25 | $63.0M | — | ||
| Q3 25 | $71.4M | — | ||
| Q2 25 | $53.8M | — | ||
| Q1 25 | $91.9M | — | ||
| Q4 24 | $182.5M | — | ||
| Q2 24 | $55.6M | — | ||
| Q1 24 | $94.2M | — | ||
| Q4 23 | $41.6M | — |
股东权益PRMERZLV
| Q4 25 | $120.9M | — | ||
| Q3 25 | $161.8M | — | ||
| Q2 25 | $60.9M | $-14.3M | ||
| Q1 25 | $106.9M | — | ||
| Q4 24 | $153.1M | — | ||
| Q2 24 | $196.6M | — | ||
| Q1 24 | $243.8M | — | ||
| Q4 23 | $133.1M | — |
总资产PRMERZLV
| Q4 25 | $342.7M | — | ||
| Q3 25 | $385.0M | — | ||
| Q2 25 | $279.0M | $80.1M | ||
| Q1 25 | $328.2M | — | ||
| Q4 24 | $297.5M | — | ||
| Q2 24 | $259.7M | — | ||
| Q1 24 | $311.4M | — | ||
| Q4 23 | $193.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.3M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | $-37.5M | — |
| 自由现金流率自由现金流/营收 | -4480.4% | — |
| 资本支出强度资本支出/营收 | 34.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-167.1M | — |
8季度趋势，按日历期对齐
经营现金流PRMERZLV
| Q4 25 | $-37.3M | — | ||
| Q3 25 | $-35.0M | — | ||
| Q2 25 | $-41.4M | $-4.9M | ||
| Q1 25 | $-48.9M | — | ||
| Q4 24 | $16.2M | — | ||
| Q2 24 | $-45.5M | — | ||
| Q1 24 | $-67.7M | — | ||
| Q4 23 | $-43.9M | — |
自由现金流PRMERZLV
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | — | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q2 24 | $-47.4M | — | ||
| Q1 24 | $-70.0M | — | ||
| Q4 23 | $-45.7M | — |
自由现金流率PRMERZLV
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | — | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -11849.6% | — | ||
| Q4 23 | — | — |
资本支出强度PRMERZLV
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 141.0% | — | ||
| Q1 25 | 166.6% | — | ||
| Q4 24 | 82.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 393.2% | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
